文献速递皮肤肿瘤

基因表达谱检测在局限性皮肤黑色素瘤预后中的性能:系统评价与荟萃分析

Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该系统评价与荟萃分析检索了截至2019年12月12日的PubMed/MEDLINE、Embase和Web of Science,纳入7项外部验证研究(共1450例AJCC I或II期局限性黑色素瘤患者),评估DecisionDx-Melanoma和MelaGenix两种GEP检测的预后性能。结果显示两种检测的性能随AJCC分期变化,在I期患者中正确识别复发的能力较差,提示临床效用有限。

要点

  • GEP检测在I期黑色素瘤中识别复发的能力较差(DecisionDx-Melanoma仅正确分类29%复发者)。
  • GEP检测性能随AJCC分期变化,II期复发识别率较高但无复发识别率低。
  • 现有证据提示GEP检测在I期局限性黑色素瘤中临床效用有限。

核心结论

  • GEP检测在局限性黑色素瘤患者中的预后能力随AJCC分期变化,在I期患者中正确识别复发的能力较差,提示临床效用有限。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed/MEDLINE、Embase和Web of Science(2019年12月12日),纳入7项外部验证研究(共1450例参与者)。
  • 纳入研究评估DecisionDx-Melanoma(5项)和MelaGenix(2项)两种GEP检测。
  • 采用CHARMS-PF提取数据,可行时使用随机效应模型进行荟萃分析。
  • 使用QUIPS工具评估偏倚风险,并采用GRADE改编版评估证据等级。

主要发现

  • DecisionDx-Melanoma:I期患者623例(TP 6、FN 15、FP 61、TN 541),II期患者212例(TP 59、FN 13、FP 78、TN 62)。
  • DecisionDx-Melanoma在复发患者中正确分类I期29%、II期82%;在无复发患者中正确分类I期90%、II期44%。
  • MelaGenix:I期患者88例(TP 7、FN 15、FP 15、TN 51),II期患者245例(TP 59、FN 19、FP 95、TN 72)。
  • MelaGenix在复发患者中正确分类I期32%、II期76%;在无复发患者中正确分类I期77%、II期43%。

临床怎么用

  • 临床应认识到GEP检测在I期局限性黑色素瘤中识别复发的能力较差,不应单独依赖其指导I期患者的预后判断。
  • 对于II期患者,GEP检测识别复发的能力较高但排除无复发的能力较低,需结合其他临床病理因素综合解读。

局限性

  • 仅纳入7项外部验证研究(占筛选研究的8%),证据基础有限。
  • 纳入研究的参与者年龄和性别信息未知。
  • 两种GEP检测的研究数量不平衡(DecisionDx-Melanoma 5项,MelaGenix 2项)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The performance of prognostic gene expression profile (GEP) tests for cutaneous melanoma is poorly characterized. OBJECTIVE: To systematically assess the performance of commercially available GEP tests in patients with American Joint Committee on Cancer (AJCC) stage I or stage II disease. DATA SOURCES: For this systematic review and meta-analysis, comprehensive searches of PubMed/MEDLINE, Embase, and Web of Science were conducted on December 12, 2019, for English-language studies of humans without date restrictions. STUDY SELECTION: Two reviewers identified GEP external validation studies of patients with localized melanoma. After exclusion criteria were applied, 7 studies (8%; 5 assessing DecisionDx-Melanoma and 2 assessing MelaGenix) were included. DATA EXTRACTION AND SYNTHESIS: Data were extracted using an adaptation of the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF). When feasible, meta-analysis using random-effects models was performed. Risk of bias and level of evidence were assessed with the Quality in Prognosis Studies tool and an adaptation of Grading of Recommendations Assessment, Development, and Evaluation. MAIN OUTCOMES AND MEASURES: Proportion of patients with or without melanoma recurrence correctly classified by the GEP test as being at high or low risk. RESULTS: In the 7 included studies, a total of 1450 study participants contributed data (age and sex unknown). The performance of both GEP tests varied by AJCC stage. Of patients tested with DecisionDx-Melanoma, 623 had stage I disease (6 true-positive [TP], 15 false-negative, 61 false-positive, and 541 true-negative [TN] results) and 212 had stage II disease (59 TP, 13 FN, 78 FP, and 62 TN results). Among patients with recurrence, DecisionDx-Melanoma correctly classified 29% with stage I disease and 82% with stage II disease. Among patients without recurrence, the test correctly classified 90% with stage I disease and 44% with stage II disease. Of patients tested with MelaGenix, 88 had stage I disease (7 TP, 15 FN, 15 FP, and 51 TN results) and 245 had stage II disease (59 TP, 19 FN, 95 FP, and 72 TN results). Among patients with recurrence, MelaGenix correctly classified 32% with stage I disease and 76% with stage II disease. Among patients without recurrence, the test correctly classified 77% with stage I disease and 43% with stage II disease. CONCLUSIONS AND RELEVANCE: The prognostic ability of GEP tests among patients with localized melanoma varied by AJCC stage and appeared to be poor at correctly identifying recurrence in patients with stage I disease, suggesting limited potential for clinical utility in these patients.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Marchetti MA, Coit DG, Dusza SW, et al. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020. PMID: 32745161. doi:10.1001/jamadermatol.2020.1731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。